Breast Cancer

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, head and neck cancer, breast cancer, prostate cancer, and leukemia.

Read our recap of top phase 1 and 2 breast cancer data announcements and highlights that may influence further clinical research and developments.

Drs Nunnery and Iyengar discuss lifestyle and medical interventions pertinent to breast cancer survivorship.

The addition of palbociclib to maintenance HER2-directed and endocrine therapy improved PFS vs SOC therapy alone in HER2-positive advanced breast cancer.

Read a refresh of the top FDA news in breast cancer from March 2026, including anticipated approvals and a biosimilar approval.

Read our recap of the top phase 3 breast cancer data announcements and highlights that may influence clinical practice in the near future.

Kevin Kalinsky, MD, MS, FASCO, discusses the role of integrative oncology programs and the importance of survivorship clinics within cancer care.

The biosimilar Ponlimsi is approved for all reference denosumab indications, and applications for an omalizumab biosimilar candidate have been accepted.

The top 5 OncLive TV videos of the week cover insights in bladder cancer, colorectal cancer, breast cancer, chronic myeloid leukemia, and multiple myeloma.

Kevin Kalinsky, MD, MS, FASCO, notes the advantages of collaborating with multidisciplinary tumor boards when managing metastatic breast cancer.

Sami Diab, MD, discusses the use of genomic assays for determining whether extended adjuvant therapy is needed for patients with breast cancer.

Oncology experts ask and answer multidisciplinary questions based on presentations from the 43rd Annual Miami Breast Cancer Conference.

Sami Diab, MD, discusses facets of individualized risk assessment for premenopausal patients with early-stage HR-positive, node-negative breast cancer.

Sami Diab, MD, discusses the value of the Breast Cancer Index for identifying disease recurrence risk in breast cancer after adjuvant endocrine therapy.

Sami Diab, MD, highlights the use of the BCI for guiding adjuvant hormonal therapy decision-making in patients with early-stage, HR-positive breast cancer.

The top 5 OncLive TV videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, lung cancer, breast cancer, and prostate cancer.

The FDA has cleared nivolumab/AVD for classical Hodgkin lymphoma, accepted a bezuclastinib NDA for review in nonadvanced systemic mastocytosis, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Sarah Sammons, MD, discusses how pumitamig’s dual-protein targets position it as a unique agent within the TNBC treatment arena.

First-line sacituzumab govitecan plus pembrolizumab generated efficacy and safety improvements vs chemotherapy plus pembrolizumab in PD-L1–positive mTNBC.

The NCCN guidelines endorse frontline sacituzumab govitecan alone for PD-L1–negative mTNBC and in combination with pembrolizumab for PD-L1–positive mTNBC.

The top 5 OncLive TV videos of the week cover insights in colorectal cancer, breast cancer, bladder cancer, and more

A drug withdrawal in follicular lymphoma and epithelioid sarcoma, a CRL in lung cancer, and priority review in breast cancer highlight this week's top oncology news.

PMD-026 inhibits RSK to block tumor growth signals and ER activity, a potential strategy to overcome CDK4/6 inhibitor resistance in breast cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.